



F-star Recognised as a Finalist in Two Categories of the Scrip Awards 2017

Cambridge, UK, 22 September 2017 – F-star, a biopharmaceutical company developing novel bispecific antibodies, has been selected as a finalist in two categories of the Scrip Awards 2017. The winners will be announced on 29 November in London.

The Scrip Awards, in their twelfth year, recognise the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare, with trophies spanning the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.

F-star is a finalist in the following categories:

- **“Best Partnership Alliance”** (with Denali) for delivery of medicines across the blood brain barrier (BBB)
- **“Business Development Team of the Year”** (with Denali) for the deal between F-star and Denali

Both award categories recognise the collaboration between F-star and Denali which was announced in August 2016. The collaboration combines F-star’s Modular Antibody Technology™ with Denali’s expertise in the development of therapeutics for neurological diseases and will generate Fcabs™ (antibody Fc-domains with antigen-binding activity) which can bind to transporters in the BBB. Using the “plug-and-play” properties of the platform, these Fcabs can be rapidly inserted into any existing antibody to generate a full size bispecific antibody (mAb²™) which can both cross the BBB, as well as bind to specific targets within the CNS. This mechanism has the potential to treat neurological diseases by acting on specific targets in the brain.

Denali’s collaboration agreement is with F-star Gamma Limited, F-star’s third Asset-Centric Vehicle.

John Haurum, CEO of F-star, commented, *“The Scrip Awards are one of our industry’s’ most prestigious and respected awards as they are judged by a panel of independent world-class experts from across the sector. It is a real honour to be selected as a finalist alongside our partner Denali Therapeutics in these categories”*

-Ends-

For further information, please contact:

At F-star	Media enquiries
Pierre Peotta Communications Manager +44 (0)7392 080 279 pierre.peotta@f-star.com	Instinctif Partners (EU & RoW) Sue Charles/Ashley Tapp +44 (0)20 7866 7923 F-star@instinctif.com Lazar Partners (USA) Glenn Silver +1 (0)212 867 1762 Gsilver@lazarpartners.com

About F-star

F-star is a clinical-validated biopharmaceutical company developing immuno-oncology bispecific antibody therapeutics selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star entered one programme in the clinic and a second immuno-oncology programme is heading toward IND. The company has built a comprehensive IP estate around its technology and product pipeline.

F-star's management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Merck and Denali Therapeutics. F-star has raised close to \$200M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

For more information visit www.f-star.com

About the Scrip Awards 2017

The Scrip Awards celebrates the essential role the pharmaceutical, biotech and other allied industries play in improving healthcare, with trophies spanning the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising. The Scrip Awards place on Wednesday, 29 November at the Hilton Hotel on Park Lane in London.

For more information, please visit the website: [Scrip Awards 2017](#)